Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
AstraZeneca’s MedImmune unit will collaborate with Advaxis, a U.S.-based specialist in developing cancer immunotherapies. The pair plans Phase I and II trials that combine MedImmune’s MEDI4736, an anti-PD-L1 immune checkpoint inhibitor, with Advaxis’s ADXS-HPV vaccine as a treatment for patients with certain cervical, head, and neck cancers associated with human papillomavirus. Advaxis will fund and conduct the study. MedImmune has first right of negotiation for further development of combinations involving MEDI4736 and ADXS-HPV.
This article has been sent to the following recipient: